Bard Agrees to Settle 500 Pelvic Mesh Cases

Posted in Medical Devices, News & Events, Transvaginal Mesh

The litigation against manufacturers of pelvic mesh devices continues to increase nationwide. A pelvic mesh implant is a synthetic material implanted and tied to ligaments or bone to lift and support internal organs. The implants were introduced over a decade ago, and can serve as an alternative to a hysterectomy. Thousands of women, who were allegedly uninformed about the dangers involved with the mesh implants, have since complained of injuries, including severe pain, infections and bleeding that often require follow-up surgeries.

As we have previously reported, C.R. Bard, manufacturer of the Avaulta pelvic mesh device, was believed to know of the risks associated with its device before it hit the market. There are approximately 12,500 lawsuits pending against C.R. Bard for the Avaulta device. The majority of these cases are consolidated as part of a federal multidistrict litigation (MDL) before U.S. District Judge Joseph Goodwin in the Southern District of West Virginia.

C.R. Bard has agreed to settle 500 of the pending cases for an undisclosed amount. The manufacturer has reported that it will continue to engage in settlement discussion with the remaining plaintiffs.

If you or a loved one has experienced any injury from the use of a vaginal mesh implant, please contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against a manufacturer of the vaginal mesh device.

New Jersey Court Upholds $11.1 Million Jury Award

Posted in Transvaginal Mesh

As we previously reported, an Atlantic County jury awarded a former nurse $3.35 million in compensatory damages and $7.76 million in punitive damages for injuries she suffered from a pelvic mesh implant made by Johnson & Johnson.

The Johnson & Johnson subsidiary, Ethicon, maker of the Gynecare Prolift pelvic mesh product, filed a motion requesting a new trial following the jury’s decision. The Presiding Civil Judge in Atlantic County Superior Court, Carol E. Higbee, recently denied Ethicon’s motion. Judge Higbee found that “there was strong evidence presented and multiple sources of evidence that in fact there were many problems with this product.”

More than 5,900 similar lawsuits alleging injury related to pelvic mesh devices are currently pending. If you or a loved one has experienced any injury from the use of a pelvic mesh implant, please contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Johnson & Johnson.

Boehringer Ingelheim Sanctioned Again in Pradaxa Litigation

Posted in Pradaxa®

As we have previously reported, Boehringer Ingelheim, the manufacturer of Pradaxa, has been sanctioned during the course of the federal litigation for destroying relevant documents. In a recent Case Management Order, Judge David R. Herndon, Chief Judge United States District Court, presiding over the litigation, revisited the manufacturer’s misconduct and fixed new sanctions.

In the recent Order, Judge Herndon found “the wrongs here are egregious” and observed that plaintiffs’ ability to pursue their case may have been greatly and unfairly harmed by Boehringer’s actions. Judge Herndon wrote, “the Court’s imposition of a fine is a measured action, designed to let the defendants know that the Court’s Order and the Court deserve respect.” Judge Herndon affirmed the fine of $931,500.00 that he had previously imposed. Additionally, the latest order requires Boehringer to pay certain expenses incurred by plaintiffs’ attorneys as they take depositions of individuals employed by the drug maker located in Europe. Judge Herndon is requiring Boehringer to pay plaintiffs’ counsel for necessary office space in Amsterdam as well as for the costs of traveling, videographers, interpreters and court reporters retroactively, from December 9, 2013 through August 2014.

If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.

First Two Bellwether Trials in Pradaxa Litigation Scheduled

Posted in Pradaxa®

The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur in patients treated with Pradaxa.

Judge David R. Herndon, Chief Judge of United States District Court, presiding over the litigation, recently entered scheduling orders for the first two bellwether trials. The first trial will begin on September 8, 2014, while the second trial is scheduled to begin on December 1, 2014.

If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.

Johnson & Johnson Loses First Ethicon Bellwether Trial

Posted in Transvaginal Mesh

As we have previously reported, plaintiffs have alleged that employees of Johnson & Johnson’s Ethicon unit, manufacturers of the Gynecare Prolift implant, mishandled documents related to the device. Plaintiffs recently asked the Department of Justice to launch an investigation into Ethicon’s handling of thousands of documents related to the device. Since then, other consumer advocacy groups have requested U.S. Senate investigations into the “pattern of reckless conduct” displayed by Johnson & Johnson officials.

A jury in Texas has ordered Johnson & Johnson to pay a damages award of $1.2 million to a sixty-four year old woman in the first verdict against the company over the use of its Ethicon device. The plaintiff filed a lawsuit against the pharmaceutical company when the TVT-O mesh sling implanted in her body to treat stress urinary incontinence eroded, causing severe pelvic pain and damage. Jurors ruled in favor of the plaintiff and concluded the device manufactured by the company’s Ethicon unit was defectively designed.

If you or a loved one has experienced any injury from the use of a vaginal mesh implant, please contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Johnson & Johnson.

Endo International Settles Pelvic Mesh Cases for $830 Million

Posted in Transvaginal Mesh

Endo International Plc (“Endo”) has agreed to pay $830 million to resolve legal claims from women who allege that they were injured by the company’s transvaginal mesh devices. Endo said the settlement will cover a “substantial majority” of the mesh litigation brought against its American Medical Systems subsidiary.  This settlement comes only one year after Endo agreed to pay $54.5 million to settle an undisclosed number of other mesh cases.

If you or a loved one has experienced any injury from the use of a vaginal mesh implant, please contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against a manufacturer.

Stark & Stark Mass Torts Group Authors Chapter in New Jersey Environmental Law Handbook

Posted in News & Events

Stark & Stark Shareholder Martin P. Schrama and Associates Stefanie Colella-Walsh and Matthew Taylor, members of the firm’s Mass Torts group, have co-authored the chapter “Mass Torts and Class Actions in New Jersey” in the eighth edition of the New Jersey Environmental Law Handbook. This publication breaks down environmental law in a way that is not only informative, but also easy to understand.

This particular chapter seeks to provide a better understanding of the complex litigation models used to resolve tort related environmental law causes of action in the State of New Jersey—the class action and the multicounty litigation (“MCL”). The former is a product of both federal and state law and is often used to resolve diverse disputes across the country. The latter is a New Jersey mechanism devised to efficiently resolve complex tort actions filed in state court.

Buy your copy of the New Jersey Environmental Law Handbook by clicking here.

State Attorney General Files Lawsuit Against Plavix® Manufacturers

Posted in Plavix®

As we have previously reported, the makers of Plavix®, Sanofi-Aventis and Bristol-Myers Squibb, have been fined for engaging in anti-competitive behavior related to the sale and marketing of the medication. Plavix® is a blood thinner prescribed to prevent heart attacks, strokes and blood clotting. However, the users of Plavix® have alleged various forms of severe side-effects. Reportedly, these side-effects include: gastrointestinal bleeding, cerebral bleeding, bleeding ulcers, Thrombotic Thrombocytopenic Purpura (TTP), heart attack, stroke and death.

Plavix® is the second most commonly prescribed drug on the U.S. market to prevent heart attacks and stroke.  The medication, known as a “clopidogrel,” is a blood thinner that belongs to a category of drugs called antiplatelets. The drug works to prevent blood clots.

Hawaii Attorney General David Louie recently filed a lawsuit against Bristol-Myers Squibb and Sanofi-Aventis alleging unfair and deceptive marketing of the blood-thinning drug to Hawaii consumers. The suit alleges that the manufacturers of Plavix®, began deceptively and unfairly labeling and marketing the drug in 1998 by failing to disclose that Plavix® has a diminished or no effect on approximately 30 percent of the population because they metabolize the drug poorly, due to their genetic traits or because they take other drugs that affect the body’s ability to metabolize Plavix®. The drug does not prevent heart attacks, strokes, or vascular death in such patients but instead puts them at considerable risk for gastrointestinal bleeding and other complications.

If you feel you have experienced any side-effects from taking Plavix®, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Plavix® manufacturers.

Plaintiffs Ask Department of Justice to Investigate Johnson & Johnson’s Destruction of Pelvic Mesh Documents

Posted in Transvaginal Mesh

As we have previously reported, plaintiffs have alleged that employees of Johnson & Johnson’s Ethicon unit, manufacturers of the Gynecare Prolift implant, mishandled documents related to the device. Plaintiffs recently asked the Department of Justice to launch an investigation into Ethicon’s handling of thousands of documents related to the device.

The consumer advocacy group, Corporate Action Network, wrote Attorney General Eric Holder to investigate whether Johnson & Johnson, based in New Brunswick, N.J., and CEO Alex Gorsky, committed the crimes of obstructing justice and destroying records in a federal probe. The Corporate Action Network said it plans to bring injured patients to speak at Johnson & Johnson’s annual shareholder meeting in late April.

If you or a loved one has experienced any injury from the use of a vaginal mesh implant, please contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Johnson & Johnson.

Court Orders Boehringer Ingelheim to Unseal Confidential Documents

Posted in Pradaxa®

The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur in patients treated with Pradaxa.

As we have previously reported, Judge David R. Herndon, Chief Judge of United States District Court, presiding over the litigation, recently sanctioned the manufacturer of Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc., over $931,000 for failing to preserve documents. Plaintiffs’ attorneys were concerned that the German-based drug maker continued to improperly withhold other documents related to the drug. Judge Herndon agreed and on January 29, 2014, ordered Boehringer Ingelheim to unseal 85 documents which had previously been marked as confidential. Plaintiffs will continue to request information related to the safety and marketing of Pradaxa.

If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.